Genistein : A chemopreventive factor in prostate cancer
Metadata
Show metadataAppears in the following Collection
- Institutt for klinisk medisin [10721]
Abstract
No abstract.List of papers
Paper I: Lazarevic B, Karlsen S.J, Saatcioglu F. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep. 2008 May;19(5):1231-5. The paper is removed from the thesis in DUO due to publisher restrictions. |
Paper II: Lazarevic B, Boezelijn G, Diep L.M, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg R.E, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Austlid Taskèn K, Karlsen S.J. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebocontrolled, double-blind Phase 2 clinical trial. Nutr Cancer. 2011;63(6):889-98. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1080/01635581.2011.582221 |
Paper III: Lazarevic B, Hammarstrom C, Yang J, Ramberg H, Diep L.M, Karlsen S.J, Kucuk O, Saatcioglu F, Austlid Taskèn K and Svindland A. The effects of short term genistein intervention on prostate biomarker expression in patients with localized prostate cancer prior to radical prostatectomy. Br J Nutr. 2012 Mar 8:1-10. The published version of this paper is available at: https://doi.org/10.1017/S0007114512000384 |
Paper IV: Lazarevic B, Moen A, Karlsen S.J, Egge-Jacobsen W. Disposition of synthetic genistein in humans induces genistein to genistein-phase II metabolite ratio differences in plasma and prostate tissue. Submitted. The paper is removed from the thesis in DUO due to publisher restrictions. |